1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Despite substantial clinical evidence and recommendations from international societies supporting the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for managing patients with type-2 diabetes (T2D) and chronic kidney disease (CKD), their adoption has remained limited. To address this, the nephrology quality improvement (QI) team at Hamad Medical Corporation (HMC), Qatar, implemented a key performance indicator (KPI) program in March 2022, aiming to ensure that at least 80% of eligible T2D-CKD patients at HMC were receiving SGLT2i by December 31, 2023.

The use of SGLT2i and angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in T2D-CKD patients attending nephrology clinics at HMC hospitals were assessed through retrospective surveys using a cluster-based sampling approach. Nephrology physicians were then updated on the results of these retrospective surveys as well as evidence from the SGLT2i trial and guidelines. The aims, objectives, and targets of the KPI program were clearly defined. Three additional surveys were conducted at 6-month intervals. A multifaceted QI intervention approach—combining audit, feedback, leadership engagement, and peer consultation—was implemented to drive improvement.

Retrospective surveys conducted in November 2021 and February 2022 revealed that 38% and 44% of eligible T2D-CKD patients were receiving SGLT2i therapy, compared to 98% and 99% for ACEi/ARB. Four months after implementing the KPI program, the July 2022 survey revealed no change in SGLT2i use (41%), while ACEi/ARB prescription rates remained near 100%. Following QI interventions in November 2022, the February 2023 survey revealed a significant increase in SGLT2i use, rising to 88%, with SGLT2i initiation in naive patients increasing from 34% to 61%. The final survey conducted in August 2023 showed that 84% of patients were receiving SGLT2i therapy.

Our KPI program boosted SGLT2i prescription rates for eligible T2D-CKD patients in nephrology clinics, resulting in a 47% rise from 41% to 88%. It overcame prescription inertia and accelerated the guideline adoption by combining real-time feedback, leadership engagement, and peer discussions. The sharp rise in new prescriptions following November 2022 feedback underscores its direct influence on behavior modification rather than a broader trend.

© 2025 Asim, Rahiman, Azim Baig, Al-Malki, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.50
2025-06-30
2025-12-07

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.50.html?itemId=/content/journals/10.5339/qmj.2025.50&mimeType=html&fmt=ahah

References

  1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:(24):2295–306. https://doi.org/10.1056/NEJMoa1811744
     [Google Scholar]
  2. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al.. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019; 139:(11):1384–95.
    [Google Scholar]
  3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383:(15):1436–46. https://doi.org/10.1056/NEJMoa2024816
     [Google Scholar]
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022; 102:(5S):S1–27. https://doi.org/10.1016/j.kint.2022.06.008
     [Google Scholar]
  5. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45:(12):3075–90. https://doi.org/10.2337/dci22-0027
     [Google Scholar]
  6. Fang L, Li G, Ren J, Duan J, Dong J, Liu Z. Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study. Sci Rep. 2023; 13:(1):5969. https://doi.org/10.1038/s41598-023-33211-1
     [Google Scholar]
  7. Shin JI, Xu Y, Chang AR, Carrero JJ, Flaherty CM, Mukhopadhyay A, et al.. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. J Am Coll Cardiol. 2024; 84:(8):683–93. https://doi.org/10.1016/j.jacc.2024.05.057
     [Google Scholar]
  8. Hamad Medical Corporation . Doha (QA):Hamad Medical Corporation;c2024. Available from: https://www.hamad.qa/EN/Pages/default.aspx
  9. Johns Hopkins University School of Medicine calculator. Available from: https://ckdpcrisk.org/pcr2acr
     [Google Scholar]
  10. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004; 329:: 828.
    [Google Scholar]
  11. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012; 55:(3):566–78.
    [Google Scholar]
  12. Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al.. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020; 19:(1):185.
    [Google Scholar]
  13. James G, Garcia Sanchez JJ, Carrero JJ, Kumar S, Pecoits-Filho R, Heerspink HJL, et al.. Low adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines despite clear evidence of utility. Kidney Int Rep. 2022; 7:(9):2059–70. https://doi.org/10.1016/j.ekir.2022.05.033
     [Google Scholar]
  14. Abukhalil AD, Muhanna SA, Madi MN, Al-Shami N, Naseef HA, Rabba AK. Adherence to ADA clinical guidelines in type 2 diabetes management in public health clinics in Palestine. Patient Prefer Adherence. 2024; 18:: 2667–80. https://doi.org/10.2147/PPA.S494951
     [Google Scholar]
  15. Maradia J, Joshi SS, Sohal A. Underutilization of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in diabetic nephropathy patients in government-run hospitals in India. Cureus. 2023; 15:(5):e38676. https://doi.org/10.7759/cureus.38676.
     [Google Scholar]
  16. Yi TW, O’Hara DV, Smyth B, Jardine MJ, Levin A, Morton RL. Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research. Can J Kidney Health Dis. 2023; 11:: 20543581231217857. https://doi.org/10.1177/20543581231217857
     [Google Scholar]
  17. Donohue JM, Guclu H, Gellad WF, Reddy A, Perretta L, Cunningham F, et al.. Influence of peer networks on physician adoption of new drugs. PLoS One. 2018; 13:(10):e0204826. https://doi.org/10.1371/journal.pone.0204826
     [Google Scholar]
  18. Davari M, Khorasani E, Tigabu BM. Factors influencing prescribing decisions of physicians: a review. Ethiop J Health Sci. 2018; 28:(6):795–804. https://doi.org/10.4314/ejhs.v28i6.15
     [Google Scholar]
  19. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993; 342:(8883):1317–22.
    [Google Scholar]
  20. Curry SJ. Organizational interventions to encourage guideline implementation. Chest. 2000; 118:(2 Suppl):40S–6S.
    [Google Scholar]
  21. Van der Wees PJ, Jamtvedt G, Rebbeck T, de Bie RA, Dekker J, Hendriks EJM. Multifaceted strategies may increase implementation of physiotherapy clinical guidelines: a systematic review. Aust J Physiother. 2008; 54:(4):233–41.
    [Google Scholar]
  22. Chaillet N, Dubé E, Dugas M, Audibert F, Tourigny C, Fraser WD, et al.. Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. Obstet Gynecol. 2006; 108:(5):1234–45.
    [Google Scholar]
  23. Chan WV, Pearson TA, Bennett GC, Cushman WC, Gaziano TA, Gorman PN, et al.. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI implementation science work group. J Am Coll Cardiol. 2017; 69:(8):1076–92.
    [Google Scholar]
/content/journals/10.5339/qmj.2025.50
Loading
Enhancing the use of sodium-glucose cotransporter-2 inhibitors in type-2 diabetic patients with chronic kidney disease, through a key performance indicator program
Qatar Medical Journal 2025, 50 (2025); https://doi.org/10.5339/qmj.2025.50
/content/journals/10.5339/qmj.2025.50
/content/journals/10.5339/qmj.2025.50
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): chronic kidney disease, key performance indicator, prescribing behavior, quality improvement, SGLT2 inhibitors and type-2 diabetes mellitus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error